References
Abbasi, S., & Badheeb, A. (2011). Prognostic factors in advanced non-small-cell lung cancer patients: Patient characteristics and type of chemotherapy. Lung Cancer International, 2011, 1-4. doi:10.4061/2011/152125
Ademuyiwa, F. O., Johnson, C. S., White, A. S., Breen, T. E., Harvey, J., Neubauer, M., … Hanna, N. H. (2007). Prognostic factors in stage III non-small-cell lung cancer. Clinical Lung Cancer, 8, 478-482. doi:10.3816/CLC.2007.n.031
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991). Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. Journal of Clinical Oncology, 9, 1618-1626.
Asmis, T. R., Ding, K., Seymour, L., Shepherd, F. A., Leighl, N. B., Winton, T. L., … Goss, G. D. (2008). Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group trials. Journal of Clinical Oncology, 26, 54-59. doi:10.1200/Jco.2007.12.8322
Besse, B., & Le Chevalier, T. (2012). Developments in the treatment of early NSCLC: When to use chemotherapy. Annals of Oncology, 23(Suppl. 10), x52-x59. doi:10.1093/annonc/mds347
Blanco, J. A., Toste, I. S., Alvarez, R. F., Cuadrado, G. R., Gonzalvez, A. M., & Martin, I. J. (2008). Age, comorbidity, treatment decision and prognosis in lung cancer. Age and Ageing, 37, 715-718. doi:10.1093/ageing/afn226
Bray, F., Ren, J. S., Masuyer, E., & Ferlay, J. (2012). Estimates of global cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer. Advance online publication. doi:10.1002/ijc.27711
Brown, J. K., & Radke, K. J. (1998). Nutritional assessment, intervention, and evaluation of weight loss in patients with non-small cell lung cancer. Oncology Nursing Forum, 25, 547-553.
Buccheri, G., & Ferrigno, D. (2001). Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer, 34, 433-440. doi:10.1016/S0169-5002(01)00273-2
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373-383.
Corbett, J. (2008). Laboratory tests and diagnostic procedures with nursing diagnoses (7th ed.). Upper Saddle River, NJ: Pearson/Prentice Hall.
Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860-867. doi:10.1038/Nature01322
Cox, D., & Oakes, D. (1984). Analysis of survival data. London, England: Chapman and Hall.
Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F. V., Cigolari, S., … Perrone, F. (2005). Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncology, 6, 669-677. doi:10.1016/S1470-2045(05)70255-2
Dy, S. M., Sharkey, P., Herbert, R., Haddad, K., & Wu, A. W. (2006). Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer. Critical Reviews in Oncology/Hematology, 59, 218-225. doi:10.1016/j.critrevonc.2006.04.001
Ferrigno, D., & Buccheri, G. (2003). Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Archives for Chest Disease, 59, 193-198.
Ferrigno, D., Buccheri, G., & Ricca, I. (2001). Prognostic significance of blood coagulation tests in lung cancer. European Respiratory Journal, 17, 667-673.
Firat, S., Byhardt, R. W., & Gore, E. (2002). Comorbidity and Karnofksy Performance Score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. International Journal of Radiation Oncology, Biology, Physics, 54, 357-364.
Gomez, W., Narsavage, G. L., & Garvin, B. (2007). Discharge support and readmission of older patients with lung cancer. European Respiratory Journal, 29(Suppl. 51), 208S.
Grivaux, M., Zureik, M., Marsal, L., Asselain, B., Peureux, M., Chavaillon, J. M., … Blanchon, F. (2011). Five-year survival for lung cancer patients managed in general hospitals. Revue des Maladies Respiratoires, 28, e31-e38. doi:10.1016/j.rmr.2008.07.001
Hotta, K., Fujiwara, Y., Kiura, K., Takigawa, N., Tabata, M., Ueoka, H., … Tanimoto, M. (2007). Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. Journal of Thoracic Oncology, 2, 402-407. doi:10.1097/01.JTO.0000268673.95119.c7
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249. doi:10.3322/caac.20006
Kasuga, I., Makino, S., Kiyokawa, H., Katoh, H., Ebihara, Y., & Ohyashiki, K. (2001). Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer, 92, 2399-2405. doi:10.1002/1097-0142
Maione, P., Perrone, F., Gallo, C., Manzione, L., Piantedosi, F. V., Barbera, S., … Cazzaniga, M. (2005). Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, 23, 6865-6872. doi:10.1200/Jco.2005.02.527
Maione, P., Rossi, A., Di Maio, M., & Gridelli, C. (2009). Tumor-related leucocytosis and chemotherapy-induced neutropenia: Linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer, 66, 8-14. doi:10.1016/j.lungcan.2009.02.022
Mandrekar, S. J., Schild, S. E., Hillman, S. L., Allen, K. L., Marks, R. S., Mailliard, J. A., … Jett, J. R. (2006). A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer, 107, 781-792. doi:10.1002/Cncr.22049
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436-444.
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649-655.
Paesmans, M., Sculier, J. P., Lecomte, J., Thiriaux, J., Libert, P., Sergysels, R., … Klastersky, J. (2000). Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer, 89, 523-533.
Paesmans, M., Sculier, J. P., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., … Klastersky, J. (1995). Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. Journal of Clinical Oncology, 13, 1221-1230.
Pallis, A. G., Agelaki, S., Kakolyris, S., Kotsakis, A., Kalykaki, A., Vardakis, N., … Georgoulias, V. (2008). Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer, 62, 356-363. doi:10.1016/j.lungcan.2008.03.030
Pedersen, L. M., & Milman, N. (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. European Respiratory Journal, 9, 1826-1830. doi:10.1183/09031936.96.09091826
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker, S., Jr., … Somerfield, M. R. (2004). American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. Journal of Clinical Oncology, 22, 330-353.
Read, W. L., Tierney, R. M., Page, N. C., Costas, I., Govindan, R., Spitznagel, E. L. J., & Piccirillo, J. F. (2004). Differential prognostic impact of comorbidity. Journal of Clinical Oncology, 22, 3099-3103. doi:10.1200/Jco.2004.08.040
Sarraf, K. M., Belcher, E., Raevsky, E., Nicholson, A. G., Goldstraw, P., & Lim, E. (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 137, 425-428. doi:10.1016/j.jtcvs.2008.05.046
Shitara, K., Matsuo, K., Oze, I., Mizota, A., Kondo, C., Nomura, M., … Muro, K. (2011). Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemotherapy and Pharmacology, 68, 301-307. doi:10.1007/s00280-010-1487-6
Teramukai, S., Kitano, T., Kishida, Y., Kawahara, M., Kubota, K., Komuta, K., … Fukushima, M. (2009). Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. European Journal of Cancer, 45, 1950-1958. doi:10.1016/j.ejca.2009.01.023
Tibaldi, C., Vasile, E., Bernardini, I., Orlandini, C., Andreuccetti, M., & Falcone, A. (2008). Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: A prognostic model. Journal of Cancer Research and Clinical Oncology, 134, 1143-1149. doi:10.1007/s00432-008-0378-2
Watine, J. (1998). Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": A clinical biologist's point of view. Journal of Cancer Research and Clinical Oncology, 124, 581-583. doi:10.1007/s004320050218
Wislez, M., Antoine, M., Rabbe, N., Gounant, V., Poulot, V., Lavole, A., … Cadranel, J. (2007). Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clinical Cancer Research, 13, 3518-3527. doi:10.1158/1078-0432.Ccr-06-2558